What it is
GH001 is GH Research’s lead inhaled mebufotenin program. In SCM coverage, GH001 should be treated as a company asset/program, not as a generic synonym for 5-MeO-DMT or mebufotenin.
The practical reader distinction is simple: compound-name language explains what neighborhood the program belongs to; GH001 names the specific GH Research formulation/program and its trial evidence.
Evidence tier
GH001 is currently the cleaner evidence anchor in the 5-MeO-DMT / mebufotenin lane because its treatment-resistant-depression signal has a peer-reviewed source spine. Use the PubMed/JAMA paper anchor for efficacy language and keep the claim tied to the GH001 study.
Company pipeline and clinical-trials pages are useful for program status and sponsor language. They should not replace the paper when the sentence is about clinical results.
What it is not
GH001 is not BPL-003. A GH001 result does not automatically transfer to Beckley Psytech’s intranasal 5-MeO-DMT benzoate program, and a BPL-003 topline or regulatory claim does not rewrite the evidence base for GH001.
Historical/toad/nomenclature sources can clarify where public language comes from, but they are not clinical evidence for GH001.